• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[美多芭:超过20年]

[Madopar: more than 20 years].

作者信息

Leiva C

机构信息

Servicio de Neurología, Hospital General Universitario de Alicante, España.

出版信息

Rev Neurol. 1997 Dec;25(148):1957-63.

PMID:9528041
Abstract

OBJECTIVE

To review the main landmarks which led to the introduction of levadopa in the the treatment of Parkinson's disease and the impact of levadopatherapy.

DEVELOPMENT

The introduction of levadopa was based on the results of basic scientific investigations in neurochemistry and neuropharmacology. In 1959 the possibility of dopamine being a neurotransmissor, and the role it plays in motor control, had been discovered. In 1960, Hornykiewiez and Ehringer published a paper on the existence of a marked deficit of dopamine in the caudate nucleus and putamen of patients with Parkinson's disease. Almost simultaneously, Birkmayer and Barbeau treated their patients with levadopa for the first time. However, levadopa was not introduced into clinical practice until 1967 and 1969 when Cotzias published papers establishing the principles of levadopatherapy as we now know it. Introduction of levadopa produced a markedly beneficial effect on the course and mortality of Parkinson's disease. However, it was soon seen that progression of the disease was not halted and that undesirable side effects appeared in patients on long-term treatment. This has led to the development of strategies to prolong the beneficial effects of levadopa and minimize its side effects.

CONCLUSION

More than 25 years after the introduction of levadopatherapy, it is still the mainstay of the treatment of Parkinson's disease, in combination with other medical and surgical treatment. Definitive treatment, however, will have to wait until the cause of this illness is fully understood.

摘要

目的

回顾导致左旋多巴被引入帕金森病治疗的主要里程碑事件以及左旋多巴治疗的影响。

发展历程

左旋多巴的引入基于神经化学和神经药理学的基础科学研究成果。1959年,多巴胺作为神经递质的可能性及其在运动控制中的作用被发现。1960年,霍尼基维茨和埃林格发表了一篇关于帕金森病患者尾状核和壳核中多巴胺显著缺乏的论文。几乎与此同时,比尔克迈尔和巴贝au首次用左旋多巴治疗他们的患者。然而,直到1967年和1969年科齐亚斯发表论文确立了我们现在所熟知的左旋多巴治疗原则后,左旋多巴才被引入临床实践。左旋多巴的引入对帕金森病的病程和死亡率产生了显著的有益影响。然而,很快就发现疾病的进展并未停止,并且长期治疗的患者出现了不良副作用。这导致了延长左旋多巴有益作用并将其副作用降至最低的策略的发展。

结论

左旋多巴治疗引入25年多后,它仍然是帕金森病治疗的主要手段,与其他药物和手术治疗相结合。然而,确定性的治疗必须等到这种疾病的病因被完全了解之后。

相似文献

1
[Madopar: more than 20 years].[美多芭:超过20年]
Rev Neurol. 1997 Dec;25(148):1957-63.
2
[Short history of L-Dopa].[左旋多巴简史]
Neurologia. 2002 Apr;17(4):214-7.
3
Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.左旋多巴治疗的四位先驱:阿尔维德·卡尔松、奥莱赫·霍尼基维茨、乔治·科齐亚斯和梅尔文·亚尔。
Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8.
4
Levodopa: past, present, and future.左旋多巴:过去、现在与未来。
Eur Neurol. 2009;62(1):1-8. doi: 10.1159/000215875. Epub 2008 Sep 9.
5
[Drug therapy in Parkinson's disease].[帕金森病的药物治疗]
Ned Tijdschr Geneeskd. 1999 Jan 30;143(5):234-40.
6
Parkinson's disease. A half century of progress.帕金森病。半个世纪的进展。
Neurology. 2001 Nov;57(10 Suppl 3):S1-3.
7
The history of dopamine and levodopa in the treatment of Parkinson's disease.多巴胺和左旋多巴治疗帕金森病的历史。
Mov Disord. 2008;23 Suppl 3:S497-508. doi: 10.1002/mds.22028.
8
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].[左旋多巴和苄丝肼新药剂型在帕金森病患者治疗中的益处]
Praxis (Bern 1994). 1995 Oct 24;84(43):1235-8.
9
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.(-)司来吉兰在帕金森病长期治疗中的作用。十年经验。
J Neural Transm Suppl. 1986;22:219-25.
10
[Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].[实用神经病学进展——I.帕金森病现代左旋多巴治疗的原则]
Ideggyogy Sz. 2007 Jan 20;60(1-2):61-4.

引用本文的文献

1
The Dopamine Transporter Is a New Target for Ischemic Stroke.多巴胺转运体是缺血性脑卒中的新靶点。
CNS Neurosci Ther. 2024 Oct;30(10):e70092. doi: 10.1111/cns.70092.
2
Immunomodulatory Effects Mediated by Dopamine.多巴胺介导的免疫调节作用。
J Immunol Res. 2016;2016:3160486. doi: 10.1155/2016/3160486. Epub 2016 Oct 4.